查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495992

全球自動注射器市場：2024-2029 年預測

Global Auto Injector Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 134 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年全球自動注射器市值為691.71億美元，預計複合年成長率為19.39%，到2029年市場規模將達到2391.45億美元。

自動注射器是一種帶有彈簧針頭的注射器，預先裝有一定劑量的藥物或藥物。與傳統注射器相比，自動注射器提供的便利性和易用性增加了對自動注射器的需求。它們受到廣泛的青睞，因為與傳統注射器相比，它們可以減少患者的焦慮和恐慌。

慢性疾病患者數量的增加正在推動全球自動注射器市場的成長。與傳統注射器相比，自動注射器普及和接受的主要因素之一是自動注射器減少了患者的焦慮。此外，由於自動注射器預先裝有藥物，因此它提高了自動注射器對醫療專業人員的有效性和便利性。自動注射器報告的錯誤率低於傳統注射器。

主要市場參與者對醫療藥物注射研究和技術開發的大量投資也促進了自動注射器市場的成長。此外，居家醫療診斷和醫療保健的不斷成長趨勢也增加了對全球自動注射器市場的需求。由於過敏反應病例的增加，自動注射器廣泛用於自行注射腎上腺素以預防過敏反應，這也推動了自動注射器市場的成長。

市場促進因素：

  • 預計慢性疾病患者數量的增加將推動自動注射器市場的發展。

慢性疾病患者數量的增加是推動全球自動注射器市場成長的主要因素之一。過敏反應病例的增加也推動了自動注射器市場的成長，因為治療過敏反應的藥物通常是在自動注射器的幫助下自行注射給患者。

根據世界過敏組織 (WAO) 全球情勢，成人過敏反應病例的比例高於兒童。患有過敏反應的成年人和老年人主要尋求自動注射器的幫助來服用腎上腺素等藥物。根據 PAHO（泛美衛生組織）的數據，約 2% 的美國人口面臨過敏反應的影響。

與傳統注射器相比，居家醫療文明病等的成長趨勢也推動了自動注射器的市場成長。自動注射器提供的自我管理優勢和給藥有效性正在推動全球自動注射器的市場價值。

  • 企業投資的增加預計將推動市場成長。

主要市場參與者對注射器和自動注射器的大量投資為全球自動注射器市場的成長帶來了潛力。藥品管理管理領域的研究和發展正在技術上加強和推動自動注射器領域的發展。

政府對醫療領域研發的支持也帶動了自動注射器市場的成長。 Amgen 和 Antares Pharma 等公司的大量投資和參與也導致了自動注射器領域的整合和發展。

北美地區所佔佔有率最大。

從地區來看，北美地區在全球自動注射器市場中佔據主要佔有率。自動注射器廣泛使用的過敏反應和關節炎等疾病病例的增加正在推動北美地區自動注射器市場的成長。亞太地區自動注射器市場持續成長。

由於糖尿病、類風濕性關節炎和多發性硬化症等慢性疾病的高發，北美，特別是美國和加拿大，成為自動注射器的主要市場。該地區先進的醫療基礎設施、技術進步和法規環境有助於這些設備的快速普及。病人偏好、教育和經濟因素也影響自動注射器的需求。

該地區強勁的經濟實力可能會導致自動注射器等先進醫療設備的醫療保健支出增加。總部位於北美或在北美擁有強大影響力的大型製藥和醫療設備公司的存在可能會進一步提高該地區的市場佔有率。

主要進展：

  • 2023 年 5 月 - SHL Medical 和 MoonLake Immuntherapeutics 共同開發了 MoonLake 奈米抗體 sonelokimab 的自動注射器。選擇 Molly 自動注射器技術這個模組化平台是為了減少初始投資並縮短開發時間。 SHL Medical 將提供設備開發專業知識、組裝指導和製造能力，以支援您的 sonelokimab 配方開發計劃。 MoonLake Immuntherapeutics技術長Oliver Daltrop 對此合作感到興奮。
  • 2022 年 10 月 - BioCorp 和 BD 合作，利用連網型技術來追蹤自我管理藥物治療（包括生技藥品）的依從性。 BioCorp 的 Injay 技術使用近場通訊，與用於預充式注射器的 BD UltraSafe Plus(TM) 被動護針器整合。這種整合旨在提高注射藥物的依從性和結果。
  • 2022 年 5 月 - Jabiru Healthcare 宣布推出 Qfinity(TM) 自動注射器平台。該平台是一種可重複使用的模組化解決方案，可支援皮下藥物的自我給藥，且成本低於市場上的替代品。該平台旨在讓患者自行注射各種注射劑，包括大容量、高黏度藥物，每單位注射量超過 100 次。 Qfinity+ 提供以患者為中心的外形尺寸，也解決了醫療廢棄物的挑戰，因為一次性塑膠注射器在醫療塑膠廢棄物中所佔比例最高。
  • 2022 年 5 月 - Stevanato Group 與 Owen Mumford Ltd. 合作，開始製造 Aidaptus® 自動注射器平台。透過此次合作，斯蒂瓦那托集團將模製組件、提供最終和分裝設備，並提供市場領先的預填充式注射器。組裝將在 Stevanato Group 和 Owen Mumford 的英國自動化組裝中心進行。此次合作將簡化設備生產並最大限度地發揮 Aidaptus® 平台的價值，這是一款與 1mL 和 2.25mL預填充玻璃注射器相容的多功能兩步式一次性自動注射器。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球自動注射器市場：按類型

  • 介紹
  • 一次性自動注射器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 可重複使用的自動注射器
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球自動注射器市場：依應用分類

  • 介紹
  • 類風濕性關節炎
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 過敏反應
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 多發性硬化症
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球自動注射器市場：依最終使用者分類

  • 介紹
  • 居家照護環境
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 醫院/診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球自動注射器市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按用途
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Amgen
  • Antares Pharma
  • Becton Dickinson and Company
  • Eli Lilly and Company
  • Johnson and Johnson
  • Mylan NV
  • Novartis AG
  • SHL Medical
  • Teva Pharmaceutical Industries Ltd
  • Ypsomed AG
簡介目錄
Product Code: KSI061611775

The global auto-injector market is evaluated at US$69.171 billion for the year 2022 and is projected to grow at a CAGR of 19.39% to reach a market size of US$239.145 billion by the year 2029.

Auto-injectors are syringes accompanied by a spring-charged needle with a pre-charged dosage of drugs or medicine. The convenience and user-friendliness offered by auto-injectors are increasing the demand for auto-injectors over conventional syringes. They are widely preferred over conventional syringes as they reduce anxiety and panic in patients compared to conventional syringes.

The increasing cases of chronic diseases have boosted the global auto-injector market growth. One of the major factors increasing the popularity and acceptability of auto-injectors over conventional syringes is the reduced anxiety caused by auto-injectors in patients. The pre-charged dosage of drugs in auto-injectors also increases the effectiveness and convenience of auto-injectors for medical practitioners. The percentage of errors reported in auto-injectors is lower than that of conventional syringes.

The significant investments in research and technological developments in medical drug injection by major market players are also contributing to the auto-injector market growth. The rising trend of home-based medical diagnosis and medical care also increases the demand for auto-injectors in the global market. The wide use of auto-injectors for the self-injection of epinephrine to prevent anaphylaxis is also boosting the market growth of auto-injectors as cases of anaphylaxis are increasing.

Market Drivers:

  • Rising cases of chronic diseases are anticipated to propel the global auto injector market.

The rising cases of chronic diseases are one of the major factors driving the global auto-injectors market growth. The increasing rate of anaphylaxis cases is also pushing the market growth of auto-injectors, as the drug for the treatment of anaphylaxis is usually self-administered to patients with the help of auto-injectors.

According to the global overview of WAO (World Allergic Organisation), the percentage of anaphylaxis cases is mostly reported in adults compared to children. Adults or older people affected by anaphylaxis mainly seek the support of self-administered auto-injectors for the dosage intake of drugs like epinephrine. According to PAHO (Pan American Health Organisation), about 2% of the total American population is facing the effects of anaphylaxis.

The rising trend of home-based medical care for lifestyle diseases and others is also fuelling the market growth of auto-injectors compared to conventional syringes. The benefits offered by auto-injectors in self-administration and effectiveness in dosage quantity are pushing the market value of auto-injectors globally.

  • Rising investment in companies is expected to surge the market growth.

The significant investments offered by major market players in injectors and self-injectors are giving potential to the global market growth of auto-injectors. The research and developments taking place in drug dosage administration are technically enhancing and developing the sector of auto-injectors.

The support offered by the government in research and development in the medical field is also resulting in the auto-injector market growth. The large investments and involvement of companies like Amgen and Antares Pharma are also leading to enhancement and development in the field of autoinjectors.

The North American region accounted for the largest share.

Geographically, the North American region accounts for the major market share in the global auto-injector market. The increasing cases of anaphylaxis, arthritis, and other diseases in which auto-injectors are widely used are fuelling the market growth of auto-injectors in the North American region. The Asia-Pacific region follows the market growth of the auto-injectors.

North America, particularly the United States and Canada, is a major market for auto-injectors due to its high prevalence of chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis. The region's advanced healthcare infrastructure, technological advancements, and regulatory environment contribute to the rapid adoption of these devices. Patient preferences and education, along with economic factors, also influence the demand for auto-injectors.

The region's strong economic strength may lead to higher healthcare spending on advanced medical devices like auto-injectors. The presence of major pharmaceutical and medical device companies headquartered or with a strong presence in North America can further boost the region's market share.

Key Developments:

  • May 2023- SHL Medical and MoonLake Immunotherapeutics collaborated to create an autoinjector for MoonLake's Nanobody sonelokimab, a drug designed to target inflammation sites and penetrate inflamed tissues and joints. The Molly autoinjector technology, a modular platform, was used to reduce initial investments and expedite development timelines. SHL Medical will provide device development expertise, assembly guidance, and production competencies to support the sonelokimab drug-device project. MoonLake Immunotherapeutics Chief Technical Officer Oliver Daltrop is excited about the collaboration.
  • October 2022- Biocorp and BD partnered to use connected technology to track adherence for self-administered drug therapies, including biologics. Biocorp's Injay technology, which uses Near Field Communication integrated with BD UltraSafe Plus(TM) Passive Needle Guard for prefillable syringes. The integration aims to improve adherence and outcomes of injectable drugs. The global connected drug delivery market is expected to grow at double-digit rates over the next decade due to shifts from acute care to home care and increased self-administered therapies.
  • May 2022- Jabil Healthcare introduced the Qfinity(TM) autoinjector platform, a reusable and modular solution for subcutaneous drug self-administration at a lower cost than market alternatives. The platform can handle over 100 injections per device and is designed to help patients self-administer various injectables, including larger volume, higher viscosity medicines. It offers a patient-centric form factor and addresses the challenge of medical waste, as plastic disposable syringes generate the highest percentage of medical-grade plastic waste. The Qfinity+ autoinjector also offers a connected version for remote monitoring.
  • May 2022- Stevanato Group partnered with Owen Mumford Ltd. to manufacture the Aidaptus(R) auto-injector platform, offering pharmaceutical customers a full range of capabilities. The partnership involved Stevanato Group molding components, providing final and sub-assembly equipment, and offering market-leading pre-filled syringes. Assembly carried out by both Stevanato Group and Owen Mumford at their UK automated assembly center. The collaboration aims to streamline device production and deliver the full value of the Aidaptus(R) platform, which is a versatile 2-step, single-use auto-injector that accommodates both 1mL and 2.25 mL prefilled glass syringes.

Market Segmentation:

By Type

  • Disposable autoinjectors
  • Reusable autoinjectors

By Application

  • Rheumatoid Arthritis
  • Anaphylaxis
  • Multiple sclerosis
  • Others

By End-user

  • Homecare settings
  • Hospitals & Clinics

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL AUTO INJECTOR MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Disposable autoinjectors
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Reusable autoinjectors
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL AUTO INJECTOR MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Rheumatoid Arthritis
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Anaphylaxis
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Multiple sclerosis
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL AUTO INJECTOR MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Homecare settings
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Hospitals & Clinics
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL AUTO INJECTOR MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Amgen
  • 10.2. Antares Pharma
  • 10.3. Becton Dickinson and Company
  • 10.4. Eli Lilly and Company
  • 10.5. Johnson and Johnson
  • 10.6. Mylan N.V.
  • 10.7. Novartis AG
  • 10.8. SHL Medical
  • 10.9. Teva Pharmaceutical Industries Ltd
  • 10.10. Ypsomed AG